A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis

Jahangir, Muhammad; Hussain, Irshad; Hasan, Mumtaz; Haroon, Tahir Saeed

doi:10.1046/j.1365-2133.1998.02465.x

Cited by 67 publications

(40 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Terbinafine has already demonstrated its efficacy against the Trichophyton spp. responsible for endothrix infections [2, 3, 4]. It is available in tablets of 250 mg.…”

Section: Methodsmentioning

confidence: 99%

Tinea capitis in Brussels: Epidemiology and New Management Strategy

et al. 2003

View full text Add to dashboard Cite

Background: We found pre-established directives inadequate to cope with the current increase in anthropophilic tinea capitis in Brussels. Objectives: To study new epidemiological profiles and to define new strategies for management and prevention. Patients and Methods: A total of 122 children affected by tinea capitis were followed in our department from October 1, 2001, until September 30, 2002. The results were assessed retrospectively. Results: Anthropophilic tinea capitis represented 89.34% of the cases. The implicated anthropophilic dermatophytes were by decreasing frequency: Microsporum langeronii (39.34%), Trichophyton soudanense (28.69%), Trichophyton violaceum (18.03%) and Trichophyton tonsurans (3.28%). Conclusion: The responsible pathogens reflect immigration flows originating mostly from Black and North Africa. Precise recommendations for each visit are detailed.

show abstract

“…Terbinafine has already demonstrated its efficacy against the Trichophyton spp. responsible for endothrix infections [2, 3, 4]. It is available in tablets of 250 mg.…”

Section: Methodsmentioning

confidence: 99%

Tinea capitis in Brussels: Epidemiology and New Management Strategy

et al. 2003

View full text Add to dashboard Cite

show abstract

“…A study has found terbinafine for 2 weeks to be superior in treating T. tonsurans when compared to 2 weeks of itraconazole (91.1 vs 80%) [50], while in another study, 2 weeks of itraconazole was found to be superior in treating T. violaceum than 2 weeks of terbinafine [51]. However, these studies are small and there are no large clinical trials published until this date to compare these two agents, making it inappropriate to conclude.…”

Section: Itraconazolementioning

confidence: 99%

Treatment of Tinea Capitis

Alkeswani

Cantrell²,

Elewski

2019

Skin Appendage Disord

View full text Add to dashboard Cite

Tinea capitis is a common fungal infection of the hair of the scalp affecting predominately prepubertal children. In the US, griseofulvin has been considered a first-line therapy agent for tinea capitis since the 1960s. However, it has been falling out of favor due to significant treatment failure, high cost, and long duration of treatment. Other antifungal agents have been researched as an alternative to griseofulvin. This paper will review the relevant pharmacologic properties, dosing, cost, efficacy, and adverse events profile for griseofulvin, terbinafine, itraconazole, fluconazole, and some adjuvant therapy options such as selenium sulfide shampoos and topical ketoconazole.

show abstract

“…The regimen of itraconazole 5 mg/kg/day for 4 weeks appears to be an effective way of treating tinea capitis due to endothrix infections. More recently, high cure rates have also been reported with itraconazole 5 mg/kg/day administered for 2 weeks in endothrix tinea capitis [14]. Itraconazole is also effective against tinea capitis due to M. canis (table 1).…”

Section: Discussionmentioning

confidence: 92%

“…Continuous therapy with itraconazole has been used in various regimens to manage tinea capitis [3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]. Over time there has been a trend to decrease the duration of active therapy while trying to maintain high cure rates [14].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Use of Itraconazole to Treat Cutaneous Fungal Infections in Children

et al. 1999

View full text Add to dashboard Cite

Background: Cutaneous mycoses such as tinea capitis, onychomycosis and some cases of tinea corporis/cruris, and tinea pedis/manus require oral antifungal therapy. There is relatively limited data regarding the use of the newer oral antifungal agents, e.g. itraconazole, in the treatment of these mycoses in children. Objective: We wished to determine the efficacy and safety of itraconazole continuous therapy in the management of cutaneous fungal infections in children. Methods: Children with cutaneous mycoses were treated with itraconazole in an open-label manner in 4 studies. For tinea capitis, the treatment regimens using itraconazole continuous therapy were: study 1, 3 mg/kg/day for 4 or 8 weeks; study 2, 5 mg/kg/day for 6 weeks, and study 3, 5 mg/kg/ day for 4 weeks. In a different trial, study 4, itraconazole continuous therapy 5 mg/kg/day was used to treat toenail onychomycosis (duration: 12 weeks), tinea corporis/ cruris (duration: 1 week) and tinea pedis/manus (duration: 2 weeks). Results: The efficacy rates at follow-up 12 weeks from the start of therapy in children with tinea capitis treated using the itraconazole continuous regimen were: clinical cure (CC) and mycological cure (MC) in study 1 (n = 10, Trichophyton violaceum all patients), CC 50%, MC 86%; in study 2 (n = 35, Microsporum canis 22 patients, Trichophyton sp. 12 patients), CC 82.8%, MC 80%, and in study 3 (n = 16, M. canis 11 patients, Trichophyton sp. 5 patients), (CC 66.7%, MC 78.5%. Itraconazole was also effective in the treatment of dermatomycoses in 24 children (study 4). The CC and MC rates at the follow-up 8 weeks from the start of therapy in children with dermatomycoses and 12 months in children treated for onychomycosis were: onychomycosis (n = 1, T. rubrum), CC 100%, MC 100%; tinea corporis (n = 12, M. canis 10 patients), CC 100%, MC 90%; tinea cruris (n = 3, Trichophyton sp. 2 patients), CC 100%, MC 100%; tinea manus (n = 1, T. rubrum), CC 100%, MC 100%, and tinea pedis (n = 7, T. rubrum), CC 100%, MC 100%). Adverse effects consisted of a cutaneous eruption in 1 (1.2%) of the 85 children, with mild, transient, asymptomatic elevation of liver function tests (less than twice the upper limit of normal) in 2 (3.4%) of 58 children in whom monitoring was performed. Conclusions: Itraconazole is effective and safe in the treatment of tinea capitis and other cutaneous fungal infections in children.

show abstract

A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis

Cited by 67 publications

References 11 publications

Tinea capitis in Brussels: Epidemiology and New Management Strategy

Tinea capitis in Brussels: Epidemiology and New Management Strategy

Treatment of Tinea Capitis

The Use of Itraconazole to Treat Cutaneous Fungal Infections in Children

Contact Info

Product

Resources

About